236 related articles for article (PubMed ID: 11114415)
1. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas.
Christensen ND; Pickel MD; Budgeon LR; Kreider JW
Antiviral Res; 2000 Nov; 48(2):131-42. PubMed ID: 11114415
[TBL] [Abstract][Full Text] [Related]
2. Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model.
Christensen ND; Cladel NM; Hu J; Balogh KK
Antiviral Res; 2014 Aug; 108():148-55. PubMed ID: 24946003
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences.
Christensen ND; Han R; Cladel NM; Pickel MD
Antimicrob Agents Chemother; 2001 Apr; 45(4):1201-9. PubMed ID: 11257035
[TBL] [Abstract][Full Text] [Related]
4. Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence.
Duan J; Paris W; De Marte J; Roopchand D; Fleet TL; Cordingley MG
Antiviral Res; 2000 May; 46(2):135-44. PubMed ID: 10854665
[TBL] [Abstract][Full Text] [Related]
5. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients.
Orlando G; Fasolo MM; Beretta R; Signori R; Adriani B; Zanchetta N; Cargnel A
AIDS; 1999 Oct; 13(14):1978-80. PubMed ID: 10513659
[No Abstract] [Full Text] [Related]
6. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature.
Dancey DR; Chamberlain DW; Krajden M; Palefsky J; Alberti PW; Downey GP
Chest; 2000 Oct; 118(4):1210-4. PubMed ID: 11035700
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Johnson JA; Gangemi JD
Antimicrob Agents Chemother; 1999 May; 43(5):1198-205. PubMed ID: 10223936
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
9. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
Van Cutsem E; Snoeck R; Van Ranst M; Fiten P; Opdenakker G; Geboes K; Janssens J; Rutgeerts P; Vantrappen G; de Clercq E
J Med Virol; 1995 Feb; 45(2):230-5. PubMed ID: 7775945
[TBL] [Abstract][Full Text] [Related]
11. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.
Zabawski EJ; Cockerell CJ
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):741-5. PubMed ID: 9810890
[TBL] [Abstract][Full Text] [Related]
12. Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children.
Milczuk HA
Otolaryngol Head Neck Surg; 2003 Jun; 128(6):788-94. PubMed ID: 12825028
[TBL] [Abstract][Full Text] [Related]
13. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
De Clercq E
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].
Snoeck R; Wellens W; Desloovere C; Van Ranst M; Naesens L; De Clercq E; Feenstra L
J Med Virol; 1998 Mar; 54(3):219-25. PubMed ID: 9515772
[TBL] [Abstract][Full Text] [Related]
15. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis.
Major T; Sziklai I; Czeglédy J; Gáll T; Gergely L; Szarka K
Anticancer Res; 2008; 28(4B):2169-74. PubMed ID: 18751391
[TBL] [Abstract][Full Text] [Related]
17. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.
Snoeck R; Bossens M; Parent D; Delaere B; Degreef H; Van Ranst M; Noël JC; Wulfsohn MS; Rooney JF; Jaffe HS; De Clercq E
Clin Infect Dis; 2001 Sep; 33(5):597-602. PubMed ID: 11477525
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
19. Intralesional cidofovir for recurrent respiratory papillomatosis in children.
Pransky SM; Magit AE; Kearns DB; Kang DR; Duncan NO
Arch Otolaryngol Head Neck Surg; 1999 Oct; 125(10):1143-8. PubMed ID: 10522508
[TBL] [Abstract][Full Text] [Related]
20. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).
Snoeck R; Noel JC; Muller C; De Clercq E; Bossens M
J Med Virol; 2000 Feb; 60(2):205-9. PubMed ID: 10596022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
